Back to results
US 4,970,300 AGranted
Modified factor VIII
AssigneeNew York University
InventorsAnne J. Fulton, Alan J. Johnson
Life of this patent
Estimating the term…
Abstract
Disclosed are conjugates of a protein having antihemophilic factor (Factor VIII) activity linked to nonantigenic ligands. The conjugates have longer half life than the unconjugated protein but maintain substantial Factor VIII activity.
Claims10
An infusible conjugate comprising a protein having Factor VIII activity covalently linked to a nonantigenic ligand, said conjugate:
- being activatable by thrombin;
- retaining at least a substantial portion of the activity of said protein prior to conjugation;
- and
- having a sufficiently prolonged in vivo disappearance time compared to said protein in the unconjugated state to at least compensate for any loss of activity of said conjugate compared to said unconjugated protein.
1 more element
Dependencies are inferred from the claim text.